Targeted therapies and radiotherapy in lung cancer

被引:6
作者
Hennequin, C. [1 ,2 ]
机构
[1] APHP, Hop St Louis, Serv Cancerol Radiotherapie, F-75010 Paris, France
[2] Ctr Univ Orsay, Inst Curie, INSERM, U612, F-91405 Orsay, France
来源
CANCER RADIOTHERAPIE | 2007年 / 11卷 / 1-2期
关键词
targeted therapies; radiotherapy; lung cancer;
D O I
10.1016/j.canrad.2006.09.036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Targeted therapies are now more often used in lung cancer. Inhibitors of EGFR and of angiogenesis have demonstrated a certain activity in this disease. Some experimental in vitro or in vivo studies are in favour of combined targeted therapies and radiation. For example, additive or supra-additive effects have been shown when inhibitors of the EGFR tyrosine kinase were given with radiation. In advanced lung cancer, the combination of bevacizumab with chemotherapy was demonstrated to produce better survival outcomes. But a high rate of fatal hemoptysis was reported with this drug, particularly for central and squamous tumors. This could be a limitation for its use in combination with radiation. Drugs with multiple targets are becoming available; their association with radiation seems to be promising. (c) 2006 Elsevier Masson SAS.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 73 条
  • [1] Akimoto T, 1999, CLIN CANCER RES, V5, P2884
  • [2] Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
    Baumann, M
    Krause, M
    [J]. RADIOTHERAPY AND ONCOLOGY, 2004, 72 (03) : 257 - 266
  • [3] Bianco C, 2002, CLIN CANCER RES, V8, P3250
  • [4] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    Bonner, JA
    Harari, PM
    Giralt, J
    Azarnia, N
    Shin, DM
    Cohen, RB
    Jones, CU
    Sur, R
    Raben, D
    Jassem, J
    Ove, R
    Kies, MS
    Baselga, J
    Youssoufian, H
    Amellal, N
    Rowinsky, EK
    Ang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) : 567 - 578
  • [5] Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer
    Bunn, PA
    Franklin, W
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (05) : 38 - 44
  • [6] Camphausen K, 2001, CANCER RES, V61, P2207
  • [7] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [8] CARTER CA, 2006, CANC CHEMOTHER PHARM
  • [9] Ciardiello F, 2003, CLIN CANCER RES, V9, P1546
  • [10] Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
    Ciardiello, F
    Bianco, R
    Caputo, R
    Caputo, R
    Damiano, V
    Troiani, T
    Melisi, D
    De Vita, F
    De Placido, S
    Bianco, AR
    Tortora, G
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (02) : 784 - 793